Skip to main content
HUMHumana Inc.Sell5.0·$378.93-0.08%
Open full analysis

Humana Inc. (HUM) Stock Analysis

SellVALUE-TRAP 2/5Moderate Confidence

Healthcare · Healthcare Plans

Sell if holding. Engine safety override at $378.93: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Below-average business quality.

Humana provides Medicare Advantage and Medicaid insurance through its Insurance segment, plus pharmacy, primary care, and home health services through CenterWell. Revenue is 83% from federal government contracts—primarily Medicare—serving approximately 15 million medical plan... Read more

$378.93-1.8% A.UpsideScore 5.0/10#7 of 11 Healthcare Plans
QualityF-score7 / 9FCF yield3.14%
IncomeYield0.93%(5y avg 0.97%)Payout37.78%sustainable
Stop $354.30Target $371.91(resistance)A.R:R -1.9:1
Analyst target$301.63-20.4%24 analysts
$371.91our TP
$378.93price
$301.63mean
$195
$441

Sell if holding. Engine safety override at $378.93: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 44d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and news legal. Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-15

Recent Developments — Humana Inc.

Generated 2026-06-15T18:11:46Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Jul 29, 202644d to earnings· next earnings call

Thesis

Rewards
Recent Analyst detected in news
Risks
Target reached (-28.3% upside)
Quality below floor (4.0 < 4.0)
Value-trap signals (2/5): Margin compression (op margin -157.9%), Negative free cash flow

Key Metrics

P/E (TTM)40.5
P/E (Fwd)24.1
Mkt Cap$45.5B
EV/EBITDA11.3
Profit Mgn0.8%
ROE6.3%
Rev Growth23.5%
Beta0.77
Dividend0.93%
Rating analysts33

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C0.83neutral
IV45%normal

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

10 dimensions · all in-band

GatesA.R:R -1.9=NEGATIVENEWS LEGALMomentum 6.7>=5.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.70EARNINGS PROXIMITY 44d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
89 · Overbought
20D MA 50D MA 200D MAGOLDEN CROSSSupport $293.36Resistance $379.50

Price Targets

$354
$372
A.Upside-1.9%
A.R:R-1.9:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-28.3% upside)
! Quality below floor (4.0 < 4.0)
! Value-trap signals (2/5): Margin compression (op margin -157.9%), Negative free cash flow

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-29 (44d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HUM stock a buy right now?

Sell if holding. Engine safety override at $378.93: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $354.30. Score 5.0/10, moderate confidence.

What is the HUM stock price target?

Take-profit target: $371.91 (-1.8% upside). Prior stop was $354.30. Stop-loss: $354.30.

What are the risks of investing in HUM?

Target reached (-28.3% upside); Quality below floor (4.0 < 4.0); Value-trap signals (2/5): Margin compression (op margin -157.9%), Negative free cash flow.

Is HUM overvalued or undervalued?

Humana Inc. trades at a P/E of 40.5 (forward 24.1). TrendMatrix value score: 5.0/10. Verdict: Sell.

What do analysts say about HUM?

33 analysts cover HUM with a consensus score of 3.5/5. Average price target: $302.

What does Humana Inc. do?Humana provides Medicare Advantage and Medicaid insurance through its Insurance segment, plus pharmacy, primary care,...

Humana provides Medicare Advantage and Medicaid insurance through its Insurance segment, plus pharmacy, primary care, and home health services through CenterWell. Revenue is 83% from federal government contracts—primarily Medicare—serving approximately 15 million medical plan members. Florida is the largest single state with 14% of consolidated premiums revenue.

Related stocks: OSCR (Oscar Health, Inc.) · CI (The Cigna Group) · CVS (CVS Health Corporation) · CNC (Centene Corporation) · ELV (Elevance Health, Inc.)
Home Stocks HUM

Latest news

Latest News

Benzinga4d agoCONCERNLegal
Benzinga4d agoAnalyst
Benzinga5d ago
Benzinga7d ago
Benzinga7d agoAnalyst
Benzinga11d agoAnalyst
Benzinga11d ago
Benzinga11d agoAnalyst
Benzinga14d ago
Benzinga15d agoEarnings
Benzinga21d ago
Benzinga26d agoAnalyst
Benzinga33d agoLegal
Benzinga34d ago
Benzinga45d agoAnalyst
Benzinga46d agoAnalyst
Benzinga46d agoAnalyst
Benzinga46d agoAnalyst
Benzinga46d agoAnalyst
Benzinga47d ago
Loading more...